More recently, the phase III ENGOT-OV16/NOVA study investigated niraparib maintenance therapy or placebo in patients with platinum-sensitive recurrent ovarian cancer previously treated with two or more platinum-based regimens who were stratified according to whether they did or did not have a germline mutation in BRCA1/2 [76]. This evidence concerns the gene BRCA1 and ovarian carcinoma.